Melanoma trial studying why immunotherapy stops working
Part of Cancer, Skin clinical trials.
This study looks at how melanoma cells “use energy” (tumor metabolism) to understand why immunotherapy can become less effective over time. If you are starting immunotherapy for advanced skin melanoma, the results may help improve future treatments for resistance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have stage III melanoma that cannot be removed by surgery or confirmed stage IV skin melanoma, and you will start immunotherapy for the first time.
- Your general ability to carry out daily activities is good (performance status 0–1).
- You can provide your BRAF test result (the study says you can still join even if BRAF is not positive).
- If you could become pregnant, you can use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial is testing a simple blood test (liquid biopsy) to track how well melanoma responds to immunotherapy. It might help doctors decide if treatment is working or needs to be changed.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Hear when a new Melanoma (Skin) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.